AU2022306397A1 - Circulating microrna signatures for pancreatic cancer - Google Patents

Circulating microrna signatures for pancreatic cancer Download PDF

Info

Publication number
AU2022306397A1
AU2022306397A1 AU2022306397A AU2022306397A AU2022306397A1 AU 2022306397 A1 AU2022306397 A1 AU 2022306397A1 AU 2022306397 A AU2022306397 A AU 2022306397A AU 2022306397 A AU2022306397 A AU 2022306397A AU 2022306397 A1 AU2022306397 A1 AU 2022306397A1
Authority
AU
Australia
Prior art keywords
hsa
seq
mir
quantifying
specifically hybridizes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022306397A
Other languages
English (en)
Inventor
Dipanjan Chowdhury
Wojciech FENDLER
Konrad STAWISKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical University Of Lodz
Dana Farber Cancer Institute Inc
Original Assignee
Medical Univ Of Lodz
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Univ Of Lodz, Dana Farber Cancer Institute Inc filed Critical Medical Univ Of Lodz
Publication of AU2022306397A1 publication Critical patent/AU2022306397A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022306397A 2021-07-09 2022-07-09 Circulating microrna signatures for pancreatic cancer Pending AU2022306397A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220195P 2021-07-09 2021-07-09
US63/220,195 2021-07-09
PCT/US2022/036608 WO2023283476A2 (en) 2021-07-09 2022-07-09 Circulating microrna signatures for pancreatic cancer

Publications (1)

Publication Number Publication Date
AU2022306397A1 true AU2022306397A1 (en) 2024-01-25

Family

ID=84801035

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022306397A Pending AU2022306397A1 (en) 2021-07-09 2022-07-09 Circulating microrna signatures for pancreatic cancer

Country Status (6)

Country Link
US (1) US20250092460A1 (enExample)
EP (1) EP4367257A4 (enExample)
JP (1) JP2024527370A (enExample)
AU (1) AU2022306397A1 (enExample)
CA (1) CA3223723A1 (enExample)
WO (1) WO2023283476A2 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055117A1 (en) * 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
CN105102637B (zh) * 2013-04-17 2018-05-22 Lg电子株式会社 提取胰腺癌诊断生物标志物的方法、用于该方法的计算装置、胰腺癌诊断生物标志物以及包含该生物标志物的胰腺癌诊断装置
CA3018048A1 (en) * 2016-03-31 2017-10-05 Toray Industries, Inc. Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor
WO2018129535A1 (en) * 2017-01-09 2018-07-12 Dana-Farber Cancer Institute, Inc. Circulating microrna signatures for ovarian cancer
BR102018003587A2 (pt) * 2018-02-23 2020-07-07 Onkos Diagnósticos Moleculares Ltda Me método e kit para detecção de tipo de tumor de tireoide
CN109055557B (zh) * 2018-09-11 2022-11-29 朱伟 一种与胰腺癌辅助诊断相关的血清miRNA标志物及其应用

Also Published As

Publication number Publication date
JP2024527370A (ja) 2024-07-24
WO2023283476A2 (en) 2023-01-12
WO2023283476A3 (en) 2023-03-09
EP4367257A2 (en) 2024-05-15
US20250092460A1 (en) 2025-03-20
WO2023283476A9 (en) 2023-11-23
CA3223723A1 (en) 2023-01-12
EP4367257A4 (en) 2025-10-15

Similar Documents

Publication Publication Date Title
US12385099B2 (en) Circulating microrna signatures for ovarian cancer
JP7466157B2 (ja) 膵臓がんの検出キット又はデバイス及び検出方法
US20140162887A1 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
US20180142303A1 (en) Methods and compositions for diagnosing or detecting lung cancers
US20230227914A1 (en) Biomarkers of oral, pharyngeal and laryngeal cancers
US20230257826A1 (en) Methods for predicting prostate cancer and uses thereof
JP2019122412A (ja) Ｍｉｒｎａ比率を使用する肺がん決定
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
US20190185944A1 (en) Methods for diagnosing and treating esophageal cancer
JP6611411B2 (ja) 膵臓がんの検出キット及び検出方法
US20250092460A1 (en) Circulating microrna signatures for pancreatic cancer
US20240254566A1 (en) Analysis method, kit, and detection device
JP2015139440A (ja) 胆管がんの検出キット及び検出方法
CN114746551A (zh) 大肠癌诊断用标志物、辅助大肠癌的诊断的方法、收集数据以用于大肠癌诊断的方法、大肠癌的诊断试剂盒、大肠癌治疗药物、大肠癌的治疗方法、大肠癌的诊断方法
WO2025105011A1 (en) Method for determining pancreatic cancer
Liu et al. Identification of Key Genes and Pathways Associated with Adriamycin Resistance in Breast Cancer
WO2025217467A1 (en) Occult blood mrna biomarkers paired with dna/rna mutations and dna methylation
JP2023152484A (ja) 乳癌の決定および治療の方法